Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Market Closed - Nasdaq Other stock markets 01:30:00 13/03/2026 am IST			5-day change	1st Jan Change
15.46 ^USD	-3.86%		+3.48%	-11.61%

12/03	Summit Therapeutics Inc. Presents at The Citizens Life Sciences Conference 2026, Mar-11-2026 02:15 PM
03/03	Summit Therapeutics Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 02:30 PM

Transcript : Summit Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 02

Published on 03/13/2024 at 12:05 am IST

S&P Capital IQ

Presenter Speech
Carter L. Gould (Analysts)

Good afternoon, and welcome to Day 1 of the Barclays Global Healthcare Conference. My name is Carter Gould covering analyst here in the U.S. biopharma space.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Summit Therapeutics Inc.

12/03	Summit Therapeutics Inc. Presents at The Citizens Life Sciences Conference 2026, Mar-11-2026 02:15 PM
03/03	Summit Therapeutics Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 02:30 PM
24/02	Summit Therapeutics Inc., Q4 2025 Earnings Call, Feb 23, 2026
24/02	Summit Therapeutics Q4 Net Loss Widens, Yearly Cash Equivalents Rise	MT
24/02	Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q4 Adjusted Loss $0.14 per Share, vs. FactSet Est of $-0.09	MT
24/02	Summit Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
09/02	Avacta appoints new chief scientific officer, plans clinical trials	AN
09/02	Avacta Therapeutics Announces Executive Changes	CI
29/01	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	CI
29/01	Summit Therapeutics Says US FDA Accepts BLA for Ivonescimab	MT
14/01	AbbVie Enters Cancer Treatment Space via RemeGen Licensing Deal, UBS Says	MT
13/01	Summit Therapeutics Inc. Announces Submission of Biologics License Application to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC	CI
13/01	Summit Therapeutics Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 09:45 AM
12/01	Summit Therapeutics, GSK Team up on Clinical Trial for Combination Cancer Therapy	MT
12/01	Summit Therapeutics Files Marketing Application for Lung Cancer Therapy	MT